GLP1R and myocardial infarction: GLP-1 RA treatment resulted in a decreased risk of 3P-MACE compared to DPP4i (23.5 vs. 34.9 occurrences per 1000 person-years; HR: 0.67; 95% CI: 0.53-0.86; P = 0.002). GLP-1 RA initiators had decreased rates of myocardial infarction (HR: 0.67; 95% CI: 0.50-0.91; P = 0.011) and all-cause mortality (HR: 0.58; 95% CI: 0.35-0.96; P = 0.034).